Search results for "THROMBOSIS"

showing 10 items of 630 documents

'Pulmonary thrombosis in situ': risk factors, clinic characteristics and long-term evolution.

2020

: Pulmonary embolism typically occurs from deep venous thrombosis (DVT). However, not always a DVT can be identified, and 'in situ' generation of pulmonary embolism has been considered, referred to in the literature as 'De novo pulmonary embolism' (DNPE). The objective of the study is to assess risk factors, comorbidities, clinic characteristics and long-term evolution of patients with pulmonary embolism in the absence of an identified source. Retrospective study of 280 patients with pulmonary embolism, 190 pulmonary embolisms with DVT group and 90 (32%) pulmonary embolism without DVT (DNPE group), admitted to an Internal Medicine Department of a tertiary hospital from January 2012 to Decem…

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk-TakingRisk FactorsInternal medicinemedicineHumansAgedRetrospective StudiesCOPDbusiness.industryRespiratory infectionRetrospective cohort studyHematologyGeneral MedicineOdds ratiomedicine.diseasePulmonary embolismVenous thrombosisEmbolismHeart failureFemalebusinessPulmonary Embolism030215 immunologyBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Impact of concomitant deep or superficial venous thrombosis of the legs on survival of patients with pulmonary embolism

2019

Pulmonary embolism (PE) is a frequent cause of death and morbidity. A few studies suggest that clot burden in pulmonary artery bed is related to PE patients' survival, but the impact of concomitant deep venous thrombosis and/or thrombophlebitis (DVT) on short-term survival of PE patients remains unclear. Thus, we aimed to investigate the impact of DVT on adverse outcomes in PE patients.Patients of the nationwide inpatient sample with PE (ICD-code I26) were stratified for DVT (ICD-code I80) and compared for patient characteristics, risk stratification markers, treatments and outcomes. Impact of concomitant DVT on adverse in-hospital outcomes was tested.Overall, 346,586 PE patients (53.3% fem…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyThrombophlebitis03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicine.arterymedicineHumanscardiovascular diseases030212 general & internal medicineCause of deathVenous ThrombosisInpatientsLegbusiness.industryCancermedicine.diseasePulmonary embolismVenous thrombosisConcomitantPulmonary arterySuperficial venous thrombosisFemalePulmonary EmbolismCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Impact of atrial fibrillation on in-hospital mortality of ischemic stroke patients and identification of promoting factors of atrial thrombi – Result…

2019

Abstract Ischemic stroke is one of the leading causes of death and disability. Atrial fibrillation (AF) is a well-recognized risk factor for ischemic stroke. We aimed to investigate the impact of AF on in-hospital mortality of ischemic stroke patients and to identify parameters associated with intra-cardiac thrombogenic material. Patients were selected by screening the nationwide sample for ischemic stroke by ICD-Code (I63), stratified for AF. In this cohort, the association between in-hospital deaths and AF was investigated. In a second study, we performed a retrospective analysis of patients who underwent transesophageal echocardiography (TEE) for various reasons, assigned these to 2 grou…

Malemedicine.medical_specialty3400left atrial appendageObservational StudyComorbidity03 medical and health sciences0302 clinical medicineInternal medicineGermanyAtrial FibrillationmedicineechocardiographyHumans030212 general & internal medicineHospital MortalityRisk factorThrombusAgedRetrospective StudiesAged 80 and overbusiness.industryIncidence (epidemiology)Mortality rateAge FactorsRetrospective cohort studyAtrial fibrillationThrombosisGeneral MedicineMiddle Agedmedicine.diseaseComorbiditymortalitystroke3. Good health030220 oncology & carcinogenesisintracardiac thrombogenic materialCohortCardiologyFemalebusinessEchocardiography TransesophagealResearch ArticleMedicine
researchProduct

Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina

2006

SummaryApplication of clopidogrel before percutaneous coronary intervention in patients with acute coronary syndrome reduces the risk of cardiac events. Clopidogrel administration before surgery increases bleeding complications after CABG. Therefore, the antithrombotic effect of the low-dose combination of clopidogrel and aspirin was investigated in an in vivo pig model of coronary artery thrombus formation with cyclic flow reductions. The platelet inhibitory effect was determined by platelet aggregation and CFR, according to the methodology described by Folts. CFR were initiated by endothelial damage and placement of a constrictor around the LAD. 30 min after CFR were established, clopidog…

Malemedicine.medical_specialtyAcute coronary syndromeTiclopidinePlatelet AggregationSwinemedicine.medical_treatmentAnginaInternal medicineAntithromboticmedicineAnimalsPlateletAngina Unstablecardiovascular diseasesAspirinAspirinbusiness.industryUnstable anginaCoronary ThrombosisPercutaneous coronary interventionHematologymedicine.diseaseClopidogrelClopidogrelDisease Models AnimalAcute DiseaseCardiologyDrug Therapy CombinationbusinessPlatelet Aggregation Inhibitorscirculatory and respiratory physiologymedicine.drugThrombosis and Haemostasis
researchProduct

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the A…

2007

Summary. Background: Tissue factor (TF) and its specific inhibitor, tissue factor pathway inhibitor (TFPI), are important contributors to the initiation of the coagulation process. Objectives: To compare plasma levels of soluble TF (sTF) and free-TFPI (f-TFPI) between patients with stable angina pectoris (SAP) and acute coronary syndrome (ACS) and to assess the impact of the two variables on long-term prognosis. Patients/methods: Patients with SAPs (n = 1146) and acute coronary syndrome (n = 523) from the AtheroGene study were included and followed for 2.3 years. Because of the strong impact of unfractionated heparin (UFH) on f-TFPI levels, but not on sTF levels, patients having received UF…

Malemedicine.medical_specialtyAcute coronary syndromeTime FactorsLipoproteinsMyocardial InfarctionRisk AssessmentSeverity of Illness IndexAngina PectorisThromboplastinCoronary artery diseaseCohort StudiesTissue factor pathway inhibitorPredictive Value of TestsInternal medicineGermanymedicineHumansMyocardial infarctionProspective StudiesAgedProportional Hazards ModelsUnstable anginabusiness.industryHazard ratioCoronary StenosisHematologySyndromeMiddle Agedmedicine.diseasePrognosisThrombosisCardiovascular DiseasesCardiologyFemalebusinessBiomarkersBlood drawingFollow-Up StudiesJournal of thrombosis and haemostasis : JTH
researchProduct

International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs.

2017

We sought to determine the test characteristics of an automated INNOVANCE D-dimer assay for the exclusion of pulmonary embolism (PE) and deep venous thrombosis (DVT) in emergency department (ED) patients using standard and age-adjusted cut-offs.Cross-sectional, international, multicenter study of consecutive patients with suspected DVT or PE in 24 centers (18 USA, 6 Europe). Evaluated patients had low or intermediate Wells PE or DVT scores. For the standard cut-off, a D-dimer result500 ng/ml was negative. For the age adjusted cut-off, we used the formula: Age (years) ∗ 10. The diagnostic standard was imaging demonstrating PE or DVT within 3 months. We calculated test characteristics using s…

Malemedicine.medical_specialtyAge adjustment030204 cardiovascular system & hematologyD-dimer assayFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicinebusiness.industryAge FactorsHematologyEmergency departmentVenous ThromboembolismMiddle Agedmedicine.diseasePulmonary embolismVenous thrombosisCross-Sectional StudiesMulticenter studyDecreased SensitivityBiological AssayFemalebusinessVenous thromboembolismThrombosis research
researchProduct

Left atrial thrombi despite anticoagulant and antiplatelet therapy

1994

To investigate risk factors for embolization in patients with echocardiographically detected left atrial thrombi and to evaluate thrombus development, we examined 29 patients with transesophageal and transthoracic echocardiography at two points during a follow-up of 18 months. We compared patients with a history of possible arterial embolization (n = 13) with those without (n = 16) in regard to age, gender, left atrial dilatation, localization of the thrombus in the left atrial cavity, spontaneous echo contrast, and atrial fibrillation. Eight patients were treated with aspirin, 20 with phenprocoumon. Only left atrial spontaneous contrast was associated with thromboembolism (10/15 patients w…

Malemedicine.medical_specialtyArterial embolismHeart Diseasesmedicine.drug_classmedicine.medical_treatmentEmbolismRisk FactorsInternal medicineAtrial FibrillationmedicineHumansMitral Valve StenosisHeart Atriacardiovascular diseasesEmbolizationThrombusAgedPeripheral Vascular DiseasesAspirinHeparinbusiness.industryArterial EmbolizationAnticoagulantThrombosisAtrial fibrillationGeneral MedicineIntracranial Embolism and ThrombosisMiddle Agedmedicine.diseaseThrombosisSurgeryEmbolismEchocardiographyPhenprocoumoncardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealDilatation PathologicFollow-Up Studiescirculatory and respiratory physiologyClinical Cardiology
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct

Eurotransplant special request for high-urgency status after liver transplantation for hepatocellular carcinoma: a case report.

2008

Hepatic artery thrombosis after liver transplantation remains a major indication for retransplantation. We report the case of a 49-year-old man with a hepatocellular carcinoma in the setting of cirrhosis associated with chronic hepatitis B and C infections who underwent split liver transplantation. The patient experienced a complicated postoperative course, characterized by 2 relaparotomies for necrosis of segment IV, and a late hepatic artery thrombosis, first discovered on postoperative day 20. His subsequent course was characterized by relapsing cholangitis and liver abscesses requiring antibiotics and percutaneous drainage. Transient control of the septic complications allowed for the f…

Malemedicine.medical_specialtyCirrhosisPercutaneousCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationNecrosisHepatic ArterymedicineHumansTransplantationDeceased donorbusiness.industryLiver NeoplasmsCancerThrombosisMiddle Agedmedicine.diseaseHepatitis BHepatitis CSurgeryTumor recurrenceLiver TransplantationTreatment OutcomeHepatocellular carcinomaSurgeryEmergenciesLiver cancerbusinessTransplantation proceedings
researchProduct

Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease.

2001

Background —Prospective data relating previous exposure to cytomegalovirus (CMV) to the risk of cardiac mortality are controversial. We investigated the effect of previous exposure to CMV infection on the risk of future cardiac disease–related death in relation to an underlying inflammatory response. Methods and Results —Coronary angiography was performed in 1134 subjects, and 989 patients with documented coronary artery disease were studied prospectively. CMV-IgG titers and interleukin (IL)-6 levels were measured before angiography. Increasing titers of CMV correlated with the elevation of IL-6 levels ( P <0.001) after adjustment for possible confounders. All patients were followed up …

Malemedicine.medical_specialtyCongenital cytomegalovirus infectionCoronary DiseaseEnzyme-Linked Immunosorbent AssayAntibodies ViralCoronary AngiographyGastroenterologyRisk AssessmentCoronary artery diseaseBetaherpesvirinaePredictive Value of TestsRisk FactorsPhysiology (medical)Internal medicineGermanymedicineOdds RatioHumansProspective StudiesRisk factorInterleukin 6AgedInflammationmedicine.diagnostic_testbiologybusiness.industryInterleukin-6Cholesterol HDLInterleukinMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisThrombosisSurvival RateC-Reactive ProteinAngiographyImmunologyCytomegalovirus Infectionsbiology.proteinRegression AnalysisFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesCirculation
researchProduct